Isocitrate dehydrogenase mutations in myeloid malignancies

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), are often driven by genetic alterations affecting cellular metabolism and epigenetic regulation.
• Mutations in isocitrate dehydrogenase (IDH) genes are found in approximately 20% of AML and 5% of MDS adult patients.
• IDH proteins (IDH1 and IDH2) are crucial enzymes in cellular processes, including the citric acid cycle and epigenetic modifications.

Purpose of the Study:

• To review the role of mutant IDH (mIDH) in myeloid malignancies.
• To discuss the neomorphic activity of mutant IDH enzymes and their downstream effects.
• To explore the clinical significance and therapeutic strategies targeting mIDH.

Main Methods:

• Review of existing literature on IDH mutations in myeloid malignancies.
• Analysis of the biochemical function of wild-type and mutant IDH proteins.
• Examination of clinical trial data for mIDH-targeted therapies.

Main Results:

• Mutant IDH enzymes produce (R)-2-hydroxyglutarate, leading to DNA and histone hypermethylation, altered gene expression, and blocked hematopoietic progenitor cell differentiation.
• The prognostic impact of mIDH mutations is influenced by co-mutational status and mutation location.
• Emerging mIDH inhibitors demonstrate tolerability and efficacy as single agents or in combination therapies for AML and MDS.

Conclusions:

• Targeting mIDH represents a promising therapeutic strategy for a subset of myeloid malignancy patients.
• Routine genetic testing for mIDH mutations is essential for patient stratification and treatment selection.
• Combination therapies targeting mIDH and other pathways may overcome clonal heterogeneity in these diseases.